Welcome to the September edition of our quarterly Algenuity newsletter!
We hope this newsletter will help you make the most of your Algem labscale photobioreactor, keep you updated on the latest Algenuity news and partnership opportunities, and also show you some interesting algal research examples from our lab and around the world.
Our CEO, Dr. Andrew Spicer, has been invited to speak at the Prospects and challenges for the development of algal biotechnology conference
held from 24 – 27th September, 2017
at Bielefeld University, Germany. The title of his talk is "Engineering the unicellular brown alga Phaeodactylum tricornutum
for high-value triterpenoid sapogenin production".
Algenuity will also be exhibiting at the Algae Biomass Summit in Salt Lake City, Utah, USA from 29th October to 1st November 2017
. Please visit Dr. Henry Taunt at our booth #217!
We recently got in touch with Victor Sanchez
, a Biochemical Engineering Ph.D. student at University College of London, and he shared a little bit about his Algem experience with us. You can read more
We would love to hear from you, our Algem users, and we would be honoured if you can share some of your experiences using our photobioreactor! If you wish to be part of an Algem user interview, please contact Sarah D'Adamo at email@example.com, and we will get in touch with you. Thank you!
The research group of Professor Saul Purton (University of College of London, UK) has recently published a paper in
Plant Biotechnology Journal
where they expressed two endolysins Cpl-1 and Pal, specific to the major human pathogen Streptococcus pneumoniae
, in the C. reinhardtii
chloroplast. The paper used Algem photobioreactors for C. reinhardtii
growth. Our Senior Strategist, Dr. Henry Taunt, is joint first author on this paper.
If you are going to a conference to share results obtained with the help of an Algem or if you have a publication accepted using our Algem, we would appreciate if you would cite us in your work. Please let us know, and we will also cite your work in our website's news section! Pictures and descriptions are welcome as well!
For further details, please email firstname.lastname@example.org
Algenuity has had the honour to be part of the EU-funded FP7 TriForC
project for the last four years from 1 October 2013 to 31 October 2017, and the TriForC is coming to the end of its term next month. The goal of TriForC was to create a "A pipeline for the discovery, sustainable production and commercial utilisation of known and novel high-value triterpenes with new or superior biological activities”.
The TriForC consortium brought together 11 academic and industrial partners from Belgium, Denmark, France, Greece, Israel, Italy, Spain and United Kingdom, and focused on building tools, resources, methods, and production systems necessary to assemble a pipeline for pharmaceutical drugs and agrochemicals.
Algenuity has been actively involved in evaluating the potential of a microalgal platform for triterpene production. We are thankful to have been part of this project and are thankful for the opportunity to collaborate with partners Europe-wide! To learn more click here
Did you like what was in here? Do you have a story or paper to share? Please send your feedback to email@example.com
We are also looking for users to interview with their Algem experiences. Send an email to the address above!
See you in three months!